At the recent EASD in Vienna, there were three presentations from the ABCD audit programme.
In a short oral presentation, Dr Alex Liarakos presented data showing that in the ABCD NHS England pilot audit of hybrid closed loop therapy (HCL) which was launched in 2021, that achieving glycaemic targets with HCL therapy in adults with type 1 diabetes is associated with lower levels of diabetes distress.
In a short oral presentation, Dr Kyaw Linn Su Khin presented data from the the ABCD semaglutide and oral semaglutide audits. The analysis demonstrated that both oral and injectable semaglutide groups experienced a reduction in HbA1c in UK real-world setting. Injectable Semaglutide was associated with a greater HbA1c reduction. It was concluded that the findings support personalized treatment choices based on individual preferences and ability to comply to oral ingestion instructions to ensure optimal absorption of oral formulation
In a short oral presentation, Dr Bob Ryder presented an analysis from the ABCD worldwide EndoBarrier registry which now has data on 1298 EndoBarrier treated patients. The analysis suggested that the considerable benefits of EndoBarrier on weight and HbA1c are achieved in 9‐months and a reduction in the recommended implantation period from 12‐ to 9‐months would reduce serious adverse events (SAE). In particular, 66% of liver abscess SAEs would be avoided if the implantation period was reduced to 9-months.
Please note, these data were collected, and submitted prior to the current pause in ABCD audit activity.
